Human Papilloma Virus (HPV) related verrucae pedis persist, seemingly evading host immune surveillance, yet sometimes disappear with inflammation. The absence, or reduction, of a cellular immune response may explain why verrucae treatments are not uniformly successful and treatment can be difficult even in immune-competent individuals. Little investigation has been undertaken into the potential benefit and efficacy of needling verrucae, a treatment modality causing HPV infected keratinocyte destruction in addition to inducing an assumed enhanced immune response. A review of clinical practice is presented, reporting the treatment method and results of data collected from a retrospective review of 45 patients. Thirty-one (69%) cases demonstrated complete resolution of verrucae following needling treatment. Three patients demonstrated reduction in size and pain whilst 11 showed no improvement. No adverse events were noted. Needling may have a place in the management of verrucae pedis in an adult population but a large scale study utilising objective measures and a control intervention would provide more detailed efficacy data along with a greater understanding of the effects of this treatment on long term immunity.
References
[1]
Gibbs, S.; Harvey, I. Topical treatments for cutaneous warts. In Cochrane Database of Systematic Reviews; John Wiley & Sons: Chichester, UK, 2006.
[2]
Kwok, C.S.; Holland, R.; Gibbs, S. Efficacy of topical treatments for cutaneous warts: A meta-analysis and pooled analysis of randomized controlled trials. Br. J. Dermatol. 2011, 165, 233–246, doi:10.1111/j.1365-2133.2011.10218.x.
[3]
Lipke, M. An armamentarium of wart treatments. Clin. Med. Res. 2006, 4, 273–293, doi:10.3121/cmr.4.4.273.
[4]
Falknor, G.W. Needling—a new technique in verruca therapy. A case report. J. Am. Podiatry Assoc. 1969, 59, 51–52.
[5]
Colver, G. Cryosurgery in podiatric practice. Podiatry Now 2005, 8, S1–S8.
[6]
Sterling, J.C.; Handfield-Jones, S.; Hudson, P.M. Guidelines for the management of cutaneous warts. Br. J. Dermatol. 2001, 144, 4–11, doi:10.1046/j.1365-2133.2001.04066.x.
[7]
Moghaddas, N. Periungual verrucae diagnosis and treatment. Clin. Podiatr. Med. Surg. 2004, 21, 651–661, doi:10.1016/j.cpm.2004.05.007.
[8]
Frazer, I.H. Interaction of human papillomaviruses with the host immune system: A well evolved relationship. Virology 2009, 384, 410–414, doi:10.1016/j.virol.2008.10.004.
[9]
Bristow, I.R.; Stiles, C.J. The treatment of stubborn plantar warts using topical 5% imiquimod cream. Podiatry Rev. 2012, 69, 6.
[10]
Powell, J. Papillomavirus research and plantar warts. Foot 1998, 8, 26–32.
[11]
Nakayama, Y.; Asagoe, K.; Yamauchi, A.; Yamamoto, T.; Shirafuji, Y.; Morizane, S.; Nakanishi, G.; Iwatsuki, K. Dendritic cell subsets and immunological milieu in inflammatory human papilloma virus-related skin lesions. J. Dermatol. Sci. 2011, 63, 173–183, doi:10.1016/j.jdermsci.2011.05.006.
[12]
Bruggink, S.C.; Gussekloo, J.; Berger, M.Y.; Zaaijer, K.; Assendelft, W.J.; de Waal, M.W.; Bavinck, J.N.; Koes, B.W.; Eekhof, J.A. Cryotherapy with liquid nitrogen versus topical salicylic acid application for cutaneous warts in primary care: Randomized controlled trial. CMAJ 2010, 182, 1624–1630.
[13]
Tyring, S. Immune-response modifiers: A new paradigm in the treatment of human papillomavirus. Curr. Ther. Res. 2000, 61, 584–596, doi:10.1016/S0011-393X(00)88011-X.
[14]
Parton, A.M.; Sommerville, R.G. The treatment of plantar verrucae by triggering cell-mediated immunity. J. Br. Pod. Med. 1994, 49, 205.
[15]
Chapman, C.; Visaya, G. Treatment of multiple verrucae by triggering cell-mediated immunity—A clinical trial. Br. J. Podiatry 1998, 1, 89–90.
[16]
Skilton, B.; Mehar, Z. Needling: A treatment option for recalcitrant verrucae pedis. Podiatry Now 2011, 14, 21–25.
[17]
Nischal, K.C.; Sowmya, C.S.; Swaroop, M.R.; Agrawal, D.P.; Basavaraj, H.B.; Sathyanarayana, B.D. A novel modification of the autoimplantation therapy for the treatment of multiple, recurrent and palmoplantar warts. J. Cutan. Aesthet. Surg. 2012, 5, 26–29, doi:10.4103/0974-2077.94332.
